Cancer survival statistics in China 2019–2021: a multicenter, population-based study

IF 7.6 Q1 ONCOLOGY
Hongmei Zeng , Rongshou Zheng , Kexin Sun , Maigeng Zhou , Shaoming Wang , Li Li , Ru Chen , Bingfeng Han , Meicen Liu , Jinhui Zhou , Mengyuan Xu , Lijun Wang , Peng Yin , Baohua Wang , Jinling You , Jing Wu , Wenqiang Wei , Jie He
{"title":"Cancer survival statistics in China 2019–2021: a multicenter, population-based study","authors":"Hongmei Zeng ,&nbsp;Rongshou Zheng ,&nbsp;Kexin Sun ,&nbsp;Maigeng Zhou ,&nbsp;Shaoming Wang ,&nbsp;Li Li ,&nbsp;Ru Chen ,&nbsp;Bingfeng Han ,&nbsp;Meicen Liu ,&nbsp;Jinhui Zhou ,&nbsp;Mengyuan Xu ,&nbsp;Lijun Wang ,&nbsp;Peng Yin ,&nbsp;Baohua Wang ,&nbsp;Jinling You ,&nbsp;Jing Wu ,&nbsp;Wenqiang Wei ,&nbsp;Jie He","doi":"10.1016/j.jncc.2024.06.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>A milestone goal of the Healthy China Program (2019–2030) is to achieve 5-year cancer survival at 43.3% for all cancers combined by 2022. To assess the progress towards this target, we analyzed the updated survival for all cancers combined and 25 specific cancer types in China from 2019 to 2021.</p></div><div><h3>Methods</h3><p>We conducted standardized data collection and quality control for cancer registries across 32 provincial-level regions in China, and included 6,410,940 newly diagnosed cancer patients from 281 cancer registries during 2008–2019, with follow-up data on vital status available until December 2021. We estimated the age-standardized 5-year relative survival overall and by site, age group, and period of diagnosis using the International Cancer Survival Standard Weights, and quantified the survival changes to assess the progress in cancer control.</p></div><div><h3>Results</h3><p>In 2019–2021, the age-standardized 5-year relative survival for all cancers combined was 43.7% (95% confidence interval [CI], 43.6–43.7). The 5-year relative survival varied by cancer type, ranging from 8.5% (95% CI, 8.2–8.7) for pancreatic cancer to 92.9% (95% CI, 92.4–93.3) for thyroid cancer. Eight cancers had 5-year survival of over 60%, including cancers of the thyroid, breast, testis, bladder, prostate, kidney, uterus, and cervix. The 5-year relative survival was generally lower in males than in females. From 2008 to 2021, we observed significant survival improvements for cancers of the lung, prostate, bone, uterus, breast, cervix, nasopharynx, larynx, and bladder. The most significant improvement was in lung cancer.</p></div><div><h3>Conclusions</h3><p>Progress in cancer control was evident in China. This highlights the importance of a comprehensive approach to control and prevent cancer.</p></div>","PeriodicalId":73987,"journal":{"name":"Journal of the National Cancer Center","volume":"4 3","pages":"Pages 203-213"},"PeriodicalIF":7.6000,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667005424000498/pdfft?md5=ba2f3e91467cd2db70ca6f11e93b38c3&pid=1-s2.0-S2667005424000498-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Center","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667005424000498","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

A milestone goal of the Healthy China Program (2019–2030) is to achieve 5-year cancer survival at 43.3% for all cancers combined by 2022. To assess the progress towards this target, we analyzed the updated survival for all cancers combined and 25 specific cancer types in China from 2019 to 2021.

Methods

We conducted standardized data collection and quality control for cancer registries across 32 provincial-level regions in China, and included 6,410,940 newly diagnosed cancer patients from 281 cancer registries during 2008–2019, with follow-up data on vital status available until December 2021. We estimated the age-standardized 5-year relative survival overall and by site, age group, and period of diagnosis using the International Cancer Survival Standard Weights, and quantified the survival changes to assess the progress in cancer control.

Results

In 2019–2021, the age-standardized 5-year relative survival for all cancers combined was 43.7% (95% confidence interval [CI], 43.6–43.7). The 5-year relative survival varied by cancer type, ranging from 8.5% (95% CI, 8.2–8.7) for pancreatic cancer to 92.9% (95% CI, 92.4–93.3) for thyroid cancer. Eight cancers had 5-year survival of over 60%, including cancers of the thyroid, breast, testis, bladder, prostate, kidney, uterus, and cervix. The 5-year relative survival was generally lower in males than in females. From 2008 to 2021, we observed significant survival improvements for cancers of the lung, prostate, bone, uterus, breast, cervix, nasopharynx, larynx, and bladder. The most significant improvement was in lung cancer.

Conclusions

Progress in cancer control was evident in China. This highlights the importance of a comprehensive approach to control and prevent cancer.

2019-2021年中国癌症生存率统计:一项基于人群的多中心研究
背景《健康中国计划(2019-2030年)》的一个里程碑式目标是,到2022年,所有癌症的5年生存率达到43.3%。为了评估实现这一目标的进展情况,我们分析了2019年至2021年中国所有癌症和25种特定癌症的最新生存率。方法我们对中国32个省级地区的癌症登记处进行了标准化数据收集和质量控制,纳入了2008年至2019年期间来自281个癌症登记处的6,410,940名新诊断癌症患者,并提供了截至2021年12月的生命体征随访数据。我们使用国际癌症生存标准权重估算了总体年龄标准化5年相对生存率,并按部位、年龄组和诊断时期进行了分类,同时量化了生存率的变化,以评估癌症控制的进展。结果2019-2021年,所有癌症的年龄标准化5年相对生存率合计为43.7%(95%置信区间[CI],43.6-43.7)。5年相对生存率因癌症类型而异,从胰腺癌的8.5%(95% CI,8.2-8.7)到甲状腺癌的92.9%(95% CI,92.4-93.3)不等。8种癌症的5年生存率超过60%,包括甲状腺癌、乳腺癌、睾丸癌、膀胱癌、前列腺癌、肾癌、子宫癌和宫颈癌。男性的 5 年相对存活率普遍低于女性。从 2008 年到 2021 年,我们观察到肺癌、前列腺癌、骨癌、子宫癌、乳腺癌、宫颈癌、鼻咽癌、喉癌和膀胱癌的生存率显著提高。结论 中国在癌症控制方面取得了明显进步。结论 中国在癌症控制方面取得了明显进步,这凸显了采取综合方法控制和预防癌症的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
14.20
自引率
0.00%
发文量
0
审稿时长
70 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信